Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens - PubMed (original) (raw)

Comparative Study

Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens

A J Conley et al. Vaccine. 1994 Apr.

Abstract

A successful prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine must elicit an immune response that will prevent establishment of the persistent viral infection. The only response shown to be effective in this regard is virus-neutralizing antibody directed against the viral gp120 hypervariable V3-loop region. Conjugate immunogens, containing cyclic peptides representing the V3 determinant covalently bound to a carrier protein, were capable of eliciting virus-neutralizing antibodies. The consistency of the response was related to peptide size. The smaller cyclic peptides, expressing relatively conserved sequences from the V3-loop apex, were poor inducers of neutralizing activity. In contrast, the largest cyclic peptides mediated neutralizing responses that were similar to those observed and previously reported for intact gp120 immunogens. A cyclic synthetic peptide expressing most of the prototypic HIV-1 MN variant V3 determinant warrants further study as a potentially effective vaccine immunogen.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources